Evidence map›Paper›PMID 39578849›Full record

ReviewStem cell research & therapy2024

Exosome crosstalk between cancer stem cells and tumor microenvironment: cancer progression and therapeutic strategies.

Qi Li, Guangpeng He, Yifan Yu, Xinyu Li, Xueqiang Peng, Liang Yang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Targeting the Dynamics Between TAMs and CAR-T Cells in Solid Tumor Therapies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  15. CD133Current cancer drug targets · 2026
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Qi Li *Department of General Surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang, 110032, China.
Guangpeng He *Department of General Surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang, 110032, China.
Yifan Yu *Department of General Surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang, 110032, China.
Xinyu LiDepartment of General Surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang, 110032, China.
Xueqiang PengDepartment of General Surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang, 110032, China. xqpeng@cmu.edu.cn.
Liang YangDepartment of General Surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang, 110032, China. 20191264@cmu.edu.cn.ORCID 0009-0005-2136-1168

Funding

China Postdoctoral Science Foundation 2021M703602National Natural Science Foundation of China 82003040National Natural Science Foundation of China 82303373National Natural Science Foundation of China 82372919Natural Science Foundation of Liaoning Province 2022-BS-137Scientific Research Fund of Liaoning Provincial Education Department LJ212410159084Scientific Research Fund of Liaoning Provincial Education Department LJ212410159099Scientific Research Fund of Liaoning Provincial Education Department LJKMZ20221210Shenyang Municipal Bureau of Science and Technology 22-321-31-02Shenyang Young and Middle-aged Science and Technology Innovation Talent Support Program RC220032Shenyang Young and Middle-aged Science and Technology Innovation Talent Support Program RC230600
6 · The paper itself

Abstract

Cancer stem cells (CSCs) represent a small yet pivotal subset of tumor cells endowed with self-renewal capabilities. These cells are intricately linked to tumor progression and are central to drug resistance, metastasis, and recurrence. The tumor microenvironment (TME) encompasses the cancer cells and their surrounding milieu, including immune and inflammatory cells, cancer-associated fibroblasts, adjacent stromal tissues, tumor vasculature, and a variety of cytokines and chemokines. Within the TME, cells such as immune and inflammatory cells, endothelial cells, adipocytes, and fibroblasts release growth factors, cytokines, chemokines, and exosomes, which can either sustain or disrupt CSCs, thereby influencing tumor progression. Conversely, CSCs can also secrete cytokines, chemokines, and exosomes, affecting various components of the TME. Exosomes, a subset of extracellular vesicles (EVs), carry a complex cargo of nucleic acids, proteins, and lipids, playing a crucial role in the communication between CSCs and the TME. This review primarily focuses on the impact of exosomes secreted by CSCs (CSC-exo) on tumor progression, including their roles in maintaining stemness, promoting angiogenesis, facilitating metastasis, inducing immune suppression, and contributing to drug resistance. Additionally, we discuss how exosomes secreted by different cells within the TME affect CSCs. Finally, we explore the potential of utilizing exosomes to mitigate the detrimental effects of CSCs or to target and eliminate them. A thorough understanding of the exosome-mediated crosstalk between CSCs and the TME could provide valuable insights for developing targeted therapies against CSCs.

Indexed as

ExosomesNeoplasmsNeoplastic Stem CellsTumor MicroenvironmentAnimalsDisease ProgressionDrug Resistance, NeoplasmHumansCancer stem cellsCancer treatmentExosomesExtracellular vesiclesTumor microenvironment

Identifiers

PMID39578849
PMCPMC11583673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.